A recent study published in JAMA Pediatrics, reported that between 2013 and 2020 the prevalence of cannabis vaping amongst teens has doubled, with approximately 1 in 3 grade 12 students vaping the substance in 2018 alone.

Smoking weed during pregnancy significantly can increase the risk of low birth weight, preterm delivery and requiring neonatal intensive care, according to a recent study published in JAMA.

The tetrahydrocannabinol, or THC, in marijuana will pass through your system to your baby and may harm your baby’s development. If you are planning to get pregnant, have learned you are pregnant or are breastfeeding, the American College of Obstetricians and Gynecologists recommends stop smoking weed, using marijuana edibles or exposing yourself to secondhand marijuana smoke.

"No drug is entirely risk free, but relative to most recreationally used drugs, psilocybin mushrooms demonstrate a good safety profile based on the rate of emergency medical treatment seeking in this sample"

A new study published in the Journal of Psychopharmacology has found that psilocybin mushrooms are a “relatively safe drug.”

That conclusion was reached after an analysis of more than 9,200 respondents who had participated in the 2017 Global Drug Survey. Specifically focusing on those who had consumed mushrooms in the past year, researchers found only 0.2 per cent of respondents sought emergency medical treatment following use.

More than half of Canadians with multiple sclerosis (MS) report using cannabis to help manage their symptoms, according to a new study.

The study, “Medical cannabis use in Canadians with multiple sclerosis,” was published in Multiple Sclerosis and Related Disorders.

Humans have used the cannabis plant for millennia, both as a recreational intoxicant and as a medicine. Although its potential benefits for MS remain unproven, emerging research suggests it can help reduce spasticity, improve sleep, and ease pain.

Medical cannabis use was legalized in Canada in 2001. Recreational use was legalized nationwide nearly two decades later in 2018.

Most Canadians diagnosed with multiple sclerosis (MS) report using cannabis to mitigate their symptoms, according to data published in the journal Multiple Sclerosis and Related Disorders.

Researchers find "statistically significant improvements" between baseline and follow-up scores after initiating medical cannabis treatment.

Researchers from Harvest Medicine in Calgary suggest their recent findings support the view that using medical cannabis can help with treating anxiety and depression.

Investigators wanted to shed light on what impact medical cannabis has on outcomes for patients experiencing anxiety or depression.

Based on information from 7,362 patients who received their medical cannabis documentation and allotment from the Calgary clinic, researchers noted improved outcomes after initiating medical cannabis treatment and at the one-year follow-up.

European medical cannabis leader Cantourage GmbH ("Cantourage") and Canada-based medical cannabis manufacturer Miracle Valley have entered a partnership that will see medical cannabis from British Columbia, Canada, brought to Germany.

Starting today, pharmacies and patients throughout Germany will have access to Miracle Valley's high-THC Mac 1 cultivar.

The Victoria Cannabis Buyers Club (VCBC) will be meeting with Health Canada on Monday to discuss dosage limits in cannabis products.

The club is currently facing about $6.5 million in fines, partially due to having higher doses in their products than approved by the organization.

VCBC, which is located on Johnson Street, has been providing cannabis products to patients with a confirmed diagnosis of a serious medical problem since 1996. Patients need a referral from a medical professional, giving them the option of cannabis over opioids for pain management.

It now has more than 8,500 patients fighting a number of conditions like diabetes, arthritis, and cancer.

City View Green Holdings Inc. (CSE: CVGR) (OTCQB: CVGRF) ("City View" or the "Company"), a leading consumer packaged goods company focused on the development of cannabis-infused edibles is pleased to announce that it has received its Cannabis Research Licence under Health Canada's Cannabis Act and Cannabis Regulations.

This licence permits City View to conduct controlled human sensory (taste) trials of cannabis infused products. Activities granted as per Health Canada include, 1) to possess cannabis for the purpose of research and 2) to produce cannabis for the purpose of research. As an essential part of new product development, taste tests will lead to City View bringing to market high quality edibles that are reflective of market trends and consumer preference.

A doctor in Alberta has been found guilty of professional misconduct for failing to follow the provincial college of physicians’ standards of practice for authorizing access to cannabis for medical purposes. 

The College of Physicians and Surgeons of Alberta (CPSA) found that Dr. Gaylord Wardell did not follow certain standards the College has in place for authorizing access to medical cannabis for someone. 

Although a four-person CPSA Hearing Tribunal found that several charges against the doctor were not proven, they did find one charge amounted to unprofessional conduct.